UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: January 22, 2018
DATE OF EARLIEST REPORTED EVENT: January 18, 2018
CORIX BIOSCIENCE, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
| Wyoming | 333-150548 | 75-3265854 | ||
(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION) | (COMMISSION FILE NO.) | (IRS EMPLOYEE IDENTIFICATION NO.) |
| 16772 West Bell Road, Suite 110-471 in Surprise, Arizona 85374 | 18662 MacAurther Boulevard, Suite 200 in Irvine, California 92612 | 34225 N. 27th Drive, Building 5, Suite 238 in Phoenix, Arizona 85085 | ||
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) | (ADDRESS OF FORMER PRINCIPAL EXECUTIVE OFFICES) | (ADDRESS OF FORMER PRINCIPAL EXECUTIVE OFFICES) |
(623) 551-5808
(ISSUER TELEPHONE NUMBER)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting Material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter. ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| -1- |
SECTION 8 – OTHER EVENTS
Item 8.01 Other Events
On January 10, 2018, Corix Bioscience, Inc., (the “Company”) issued a press release titled “Corix Bioscience, Inc. Announces Joint Venture with ChampRX.” The purpose of the press release was to announce a joint venture with ChampRX. The press release is attached hereto as an Exhibit.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
| Exhibit No. | Document |
| 99.1 | Press Release dated January 18, 2018 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| Corix Bioscience, Inc. | |
| By: | /s/Michael Ogburn |
| Name: | Michael Ogburn |
| Title: | Chief Executive Officer and President |
| Dated: | January 22, 2018 |
| -2- |